Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
melanoma
Biotech
Regeneron rocked by failure as melonama drug can't beat Keytruda
The phase 3 study of the LAG-3 inhibitor missed its primary endpoint, leaving Regeneron reeling from the second failure of a key late-stage program.
Nick Paul Taylor
May 18, 2026 4:40am
Shedding 60% of workforce, Replimune vows to continue operations
Apr 21, 2026 2:15am
Obsidian leverages Galera reverse merger to go public
Apr 14, 2026 11:20am
Replimune to lay off staff after 'disappointing' second rejection
Apr 10, 2026 1:56pm
Pfizer drops another early cancer candidate from Seagen
Mar 19, 2026 12:56pm
After R&D head exits, Immunocore CEO pairs ambition with caution
Feb 13, 2026 12:44pm
